BridgeMD
New treatment option for Carpal Tunnel Syndrome (CTS)
Official title Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome
ClinicalTrials.gov ID: NCT06593977
What this study is testing
- What it's testing
- The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Signed and dated informed consent form;
- Stated willingness to comply with all study procedures and availability for the duration of the study;
- Aged 18-65 years of age;
- In good general health;
- Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of...
You likely can't join if
- Inability to understand the clinical trial and/or sign the Informed Consent;
- Unable or unwilling to attend all of the study prescribed visits and data collection forms;
- Active infection requiring medication;
- Drug requiring diabetes mellitus;
- Collagenopathies;
- Hypothyroidism requiring medication;
See the full eligibility criteria
- Signed and dated informed consent form;
- Stated willingness to comply with all study procedures and availability for the duration of the study;
- Aged 18-65 years of age;
- In good general health;
- Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of primary carpal tunnel syndrome;
- All of the following physical examination tests must be performed; at least one must be positive:
- Physical examination demonstrates positive Phalen test;
- Physical examination demonstrates positive Tinel's test;
- Physical examination demonstrates positive monofilament test;
- ENMG demonstrates median nerve velocity and deviation consistent with the diagnosis of carpal tunnel syndrome.
- Inability to understand the clinical trial and/or sign the Informed Consent;
- Unable or unwilling to attend all of the study prescribed visits and data collection forms;
- Active infection requiring medication;
- Drug requiring diabetes mellitus;
- Collagenopathies;
- Hypothyroidism requiring medication;
- Rheumatoid arthritis requiring medication;
- Autoimmune disease requiring medication;
- Cervical nerve compression;
- Hematopoietic disorders;
- Lacertus fibrosis;
- Psychiatric disorder requiring medical treatment;
- Subject of workers compensation claim;
- History of cancer, except for basal or squamous cell skin cancer;
- Known allergic reactions to components of DYNAVISC;
- Actively participating in another clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Leuven, Belgium, Belgium
- Roeselare, Belgium, Belgium
- Araçatuba, Brazil, Brazil
- Padova, Italy, Italy
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Leuven, Belgium, Belgium; Roeselare, Belgium, Belgium; Araçatuba, Brazil, Brazil; Padova, Italy, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.